An agile & highly customizable
toolbox for drug screening
Our unique ZTX®platform is shortening the time for drug discovery by providing in-vivo data on tumor regression and metastasis inhibition of compounds within 5 days.
Screening many CDX models to find a new indication for your drug
Test a variety of cell lines derived from tumors from different anatomical locations to screen alternative indications to achieve the highest therapeutic potential.
Screening a panel of 12 tumor cell lines identifies new indications for a drug targeting hypoxia-induced tumor metabolism
Use ZTX® as an inclusion criteria in your clinical trial
How it works
- Patient tumor cells are tested in the ZTX®platform for their sensitivity toward a specific treatment/treatment combination
- Identification of patient characteristics for responders and non-responders
- Include only patients who respond to the drug candidate in the clinical trial
Output
- Stratification into likely sensitive subtypes for a specific treatment to be used as inclusion criteria for more efficient clinical trial planning
- Tool for stratification of patients for clinical trial, increasing the chances of positive outcomes in the clinical trial
- Reduce the number of patients needed in each treatment arm and save both time and costs
Identify the lead ADC candidate with the strongest tumor-targeting efficacy and minimal toxicity
The ZTX® is an excellent platform for screening antibody-drug conjugates (ADCs) due to its suitability to evaluate biodistribution and tumor targeting effect of ADCs through intravenous administration. Compare novel ADCs against standard-of-care treatment to demonstrate superior efficacy.
The ZTX® platform is also particularly well-suited for compounds that function through immune activation. Since the zebrafish larva lacks an endogenous immune system, a human immune system can be readily reconstituted to study these mechanisms of action
